CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotech that integrates computational chemistry and other advanced technologies to design breakthrough medicines and transform drug ...

Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his ...

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) and Nimbus Therapeutics, LLC today announced that the companies have signed a definitive agreement under ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus ...

Nimbus Therapeutics said yesterday it has won a $200 million milestone payment from Gilead Sciences based on progress in its clinical development of the allosteric acetyl-CoA carboxylase (ACC) ...

Gilead Sciences Inc. GILD has come up with two important corporate announcements – the company’s third tenofovir alafenamide (TAF)-based HIV drug, Descovy, has gained FDA approval and it has struck ...

Celgene and the computational chemistry company Nimbus Therapeutics are teaming up to advance R&D on small molecules that could treat a suite of immunology conditions. One Nimbus program is designing ...

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2012 /PRNewswire/ — Nimbus Data Systems, Inc., the leader in Sustainable Storage systems and software, today announced its FlashPoint Partner Program. This ...

Fifty years ago, weather forecasting began a seismic shift, one which brought meteorology and weather forecasting to a level that would be impossible without this technology. The Nimbus program ...

Gilead Sciences will acquire a Nimbus Therapeutics wholly-owned subsidiary and its acetyl-CoA carboxylase (ACC) inhibitor program—including a Phase II-bound lead candidate—for up to $1.2 billion, the ...